RANI

Rani Therapeutics Holdings Inc

RANI.US ranitherapeutics.com + Research + Basket
CIK 0001856725
Employees 69
Phone 408 457 3700
Fiscal year end December
IPO Jul 30, 2021
Address 2051 Ringwood Avenue, San Jose, CA, United States, 95131
0.59
-0.01 (-1.73%)
USD · NASDAQ
52-week range
0.57
2.63
Trading at 1% of the 52-week range
Market Cap
86.46M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.35
Div. Yield
N/A
% Institutions
46.79%
% Insiders
4.91%

1 Year

-63.5%

3 Year

-69.1%

10 Year

-94.5%
Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Actions

Add an action for RANI.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Mir A. Imran Executive Chairman 1956
Mr. Talat Imran CEO & Director 1982
Ms. Kate McKinley M.B.A. Chief Business Officer 1978
Mr. Nicholas Maestas Chief Financial Officer 1980
Mr. Alireza Javadi Ph.D. Chief Technical Officer 1984
Dr. Mir Hashim Chief Scientific Officer 1960
Ms. Bella Vazquez Senior Vice President of People & Administrative Services NA
Mr. Jesper Hoeiland M.Sc. Head of Strategy 1960
Ms. Arvinder Dhalla Vice President of Clinical Development NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Oct 23, 2025 Mir A Imran N/A Purchase 2.08M $0.60 $1.25M SEC
Oct 21, 2025 South Cone Investments Limited N/A Sale 4.00M $2.77 $11.08M SEC
Oct 20, 2025 South Cone Investments Limited N/A Sale 1.92M $2.41 $4.63M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Samsara BioCapital, LLC 10.37M Jun 30, 2026 8.98% $0.65 21.99%
RA Capital Management, LLC 8.50M Jun 30, 2026 7.36% $0.06 0.00%
Awm Investment Company Inc 7.50M Jun 30, 2026 6.50% $0.49 15.38%
Vanguard Capital Management, LLC 4.56M Jun 30, 2026 3.95% $0.00 -1.29%
SymBiosis Capital Partners, LLC 3.67M Mar 31, 2026 3.18% $5.11 -41.78%
Longaeva Partners L.P. 2.33M Jun 30, 2026 2.02% $0.04 0.00%
Polar Asset Management Partners 2.32M Jun 30, 2026 2.01% $0.03 0.00%
Siren, L.L.C. 2.00M Jun 30, 2026 1.73% $0.03 0.00%
Heights Capital Management Inc 934.58K Jun 30, 2026 0.81% $0.16 0.00%
Geode Capital Management, LLC 890.62K Jun 30, 2026 0.77% $0.00 -1.40%
Citadel Advisors Llc 642.00K Jun 30, 2026 0.56% $0.00 0.00%
Marshall Wace Asset Management Ltd 586.27K Jun 30, 2026 0.51% $0.00 0.00%
Nan Fung Group Holdings Ltd 493.58K Jun 30, 2026 0.43% $0.29 0.00%
683 Capital Management LLC 487.17K Mar 31, 2026 0.42% $0.02 0.00%
Jane Street Group LLC 485.90K Jun 30, 2026 0.42% $0.00 193.42%
Vanguard Fiduciary Trust Co 458.13K Jun 30, 2026 0.40% $0.00 0.68%
Renaissance Technologies Corp 430.74K Jun 30, 2026 0.37% $0.00 0.00%
State Street Corp 373.14K Jun 30, 2026 0.32% $0.00 0.00%
BlackRock Inc 342.11K Jun 30, 2026 0.30% $0.00 -38.57%
United Services Automobile Association 302.74K Jun 30, 2026 0.26% $0.02 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 3.65M 3.16% ▲ 0.00% Sep 30, 2026
2 Abante Quant Value FI 624.15K 0.54% ▲ 0.00% Aug 31, 2026
3 Fidelity Extended Market Index 403.63K 0.35% ▼ 0.53% Aug 31, 2026
4 Fidelity Total Market Index 138.18K 0.12% ▲ 0.00% Aug 31, 2026
5 Fidelity Series Total Market Index 115.38K 0.10% ▲ 0.00% Aug 31, 2026
6 iShares Nasdaq US Biotech ETF USD Acc 73.83K 0.06% ▲ 0.87% Sep 30, 2026
7 Vanguard Balanced Index Inv 49.89K 0.04% ▲ 0.00% Sep 30, 2026
8 Vanguard U.S. Eq Idx £ Acc 31.75K 0.03% ▲ 0.00% Sep 30, 2026
9 Luceiro Capital Value Fund FI 26.30K 0.02% ▲ 0.00% Aug 31, 2026
10 China Universal NASDAQ Bio-Tch ETF(QDII) 17.89K 0.02% ▲ 12.54% Jun 30, 2026

Financial Highlights

▼
Market Cap: $86.46M
EBITDA: $-32.24M
Book Value: $0.35
Earnings/Share: $-0.15
Profit Margin: 0.00%
Operating Margin: -516.86%
ROA (TTM): -52.99%
ROE (TTM): -172.15%
Revenue (TTM): $4.88M
Revenue/Share (TTM): $0.04
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 893.00%

Valuation Metrics

Enterprise Value: $20.92M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 115.42M
Shares Float: 82.32M
% Insiders: 4.91%
% Institutions: 46.79%
Shares Short: 8.16M
Shares Short (Prior Month): 7.25M
Short Ratio: 13.33
Short % Float: 7.26%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$1.63M
Cost of Goods Sold
adjust
$-900.00K
Gross Profit
subtotal
$733.00K
SG&A
adjust
$-19.74M
R&D
adjust
$-20.21M
Operating Income
subtotal
$-38.31M
Other / Non-Operating Items
adjust
$8.64M
Net Income
subtotal
$-29.67M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about RANI.US!